008930:KRXHanmi Science Co., Ltd Analysis

Hanmi Science (008930.KS) is trading at a steep premium, with the current price of 31,550 KRW far above the DCF‑derived fair value of 1,775 KRW, indicating an overvalued market stance. Technical metrics reinforce a cautious outlook: the stock sits below its 50‑day (35,278 KRW) and 200‑day (38,283 KRW) moving averages, the RSI hovers at 45 (neutral), while the MACD shows a modest bullish histogram (+204) but remains in negative territory. Volatility is high at ~55% over the past 30 days and beta is modest (0.69), suggesting price swings without strong market‑wide correlation.
On the fundamentals side, revenue is growing at 6.7% YoY, and a recent licensing agreement with Eli Lilly on the sonefpeglutide analog adds a notable growth catalyst. However, the company carries a heavy debt load (Debt‑to‑Equity 18.8) despite solid cash reserves, and its dividend yield is modest (0.97%) with a low payout ratio (15%). These mixed signals point to a short‑term downside risk, a medium‑term hold stance pending pipeline outcomes, and a cautious long‑term outlook.